https://pr.portlandtribune.com/article/RARE-CLASS-ACTION-REMINDER-Faruqi-andamp-Faruqi-LLP-Reminds-Ultragenyx-Pharmaceutical-RARE-Investors-of-Securities-Class-Action-Deadline-on-April-6-2026/6991c2fdf3b9ec0450c8b72e
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors...
class actionultragenyx pharmaceuticalrarereminderfaruqi
https://www.paramaribopoliticsdaily.com/article/897277931-investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-ultragenyx-pharmaceutical-inc-of-class-action-lawsuit-and
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx...
law firminvestoralertpomerantzreminds
https://biotech-insider.com/ultragenyx-angelman-antisense-drug-misses-phase-3/
Ultragenyx's Angelman Antisense Drug Misses in Phase 3
Sep 6, 2026 - Ultragenyx's antisense oligonucleotide for Angelman syndrome missed in Phase 3, removing a late-stage rare-disease asset and resetting expectations across…
antisense drugin phaseultragenyxangelmanmisses
https://curesanfilippofoundation.org/2026/01/ultragenyx-resubmits-ux111-to-fda-for-accelerated-approval-of-sanfilippo-type-a/
Ultragenyx resubmits UX111 to FDA for accelerated approval of Sanfilippo Type A
Feb 4, 2026 - Ultragenyx has officially resubmitted its application to FDA seeking accelerated approval of UX111 for Sanfilippo Syndrome type A.
accelerated approvalultragenyxresubmitsfdasanfilippo
https://www.fiercebiotech.com/biotech/ultragenyx-granted-go-ahead-to-up-doses-for-stalled-angelman-therapy-after-safety-issues
Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety...
Jan 5, 2022 - Ultragenyx Pharmaceutical and partner GeneTx Biotherapeutics have been given the go-ahead to up the dose in a phase 1/2 Angelman syndrome trial that was...
go aheadantisense therapyultragenyxgranteddoses
https://illinoiswellnessinsider.com/article/897277931-investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-ultragenyx-pharmaceutical-inc-of-class-action-lawsuit-and
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx...
law firminvestoralertpomerantzreminds
https://www.foodandbeveragenewsnetwork.com/article/946863292-ultragenyx-announces-marketing-authorisation-application-maa-submission-to-the-european-medicines-agency-ema-for-the-first-investigational-gene
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines...
marketing authorisationto theultragenyxannouncesapplication
https://www.stvincentgrenadinesindustrywire.com/article/864308955-ultragenyx-announces-sale-of-a-portion-of-future-north-american-royalties-on-crysvita-burosumab-for-400-million-to-omers-life-sciences
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab)...
of anorth americanultragenyxannouncessale
https://westvirginiabusinessdispatch.com/article/897404265-ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-lawsuit-contact-lewis-kahn-esq-at-kahn-swick-foti
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action...
ultragenyx pharmaceuticalclass actionincnoticeapril
https://www.economicreporthaiti.com/article/864309050-ultragenyx-reports-third-quarter-2025-financial-results-and-corporate-update
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update | Economic Report Haiti
third quarterfinancial resultseconomic reportultragenyxreports
https://www.israelhealthcarenews.com/article/946204876-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc-rare
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx...
on behalf oflaw firminvestoralertpomerantz
https://politicalreporterguam.com/article/897225836-kessler-topaz-meltzer-check-llp-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-lawsuit-filed-march-13-2026-lead-plaintiff
Kessler Topaz Meltzer & Check, LLP - Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class...
ultragenyx pharmaceuticalsecurities fraudkesslertopazmeltzer
https://www.middleeastsmallbusinessobserver.com/article/946863292-ultragenyx-announces-marketing-authorisation-application-maa-submission-to-the-european-medicines-agency-ema-for-the-first-investigational-gene
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines...
Middle East Small Business Observer is an online news publication focusing on sme/smb in the Middle East: Catch up with small business news from the Middle East
marketing authorisationto theultragenyxannouncesapplication
https://www.economicdigestofeurope.com/article/946863292-ultragenyx-announces-marketing-authorisation-application-maa-submission-to-the-european-medicines-agency-ema-for-the-first-investigational-gene
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines...
marketing authorisationto theultragenyxannouncesapplication
https://www.northdakotaindustrywatch.com/article/864308955-ultragenyx-announces-sale-of-a-portion-of-future-north-american-royalties-on-crysvita-burosumab-for-400-million-to-omers-life-sciences
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab)...
North Dakota Industry Watch is an online news publication focusing on industries in the North Dakota: Hottest industries and services news from North Dakota
of anorth americanultragenyxannouncessale